Crossmark

A Response to: Letter to the Editor Regarding “Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance”

Crossref DOI link: https://doi.org/10.1007/s40744-024-00739-1

Published Online: 2025-01-20

Published Print: 2025-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Batko, Bogdan https://orcid.org/0000-0003-3999-8093
Rivas, Jose L. https://orcid.org/0009-0004-6736-3962
License Information

Text and Data Mining valid from 2025-01-20

Version of Record valid from 2025-01-20
More Information

Article History

Received: 20 September 2024

Accepted: 16 December 2024

First Online: 20 January 2025

Declarations

:

: Bogdan Batko has speaking contracts, clinical trial contracts, and/or has acted as a consultant for AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, Medac, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sandoz, Sobi, and UCB. Jose L. Rivas is an employee and shareholder of Pfizer.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.

Document is current

Any future updates will be listed below